| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 72.11 | 11.1% | 7.8% |
| Total Income | 72.11 | 11.1% | 7.8% |
| Expenditure | 68.54 | 2.7% | 15.3% |
| PBT | -1.46 | 78.6% | 107.8% |
| Net Profit | -2.67 | 59.7% | 113.5% |
| OPM | 4.95% | 7.73pp | 8.41pp |
| NPM | -3.70% | 6.51pp | 28.91pp |
| EPS | -0.02 | 60.0% | 112.5% |
SkinHealth Systems Reports Q2 2026 Net Sales of $72.1 Million, Adjusted EBITDA Up 22.3%
07 Aug 2026 · 7 Aug, 1:53 am
Summary
SkinHealth Systems reported second quarter 2026 net sales of $72.1 million, a 7.8% decrease year-over-year, alongside a net loss of $(2.7) million. Despite sales pressure, adjusted EBITDA saw a 22.3% increase to $17.0 million, benefiting from improved gross margins and disciplined operating expense management. The company's strategic focus remains on strengthening its core Hydrafacial franchise and expanding its portfolio for sustainable long-term growth, though revised full-year guidance anticipates continued sales challenges.
Key Highlights
- 1
Net sales for the second quarter of 2026 decreased by 7.8% year-over-year to $72.1 million, primarily due to lower delivery systems and consumables net sales.
- 2
The company reported a net loss of $(2.7) million in Q2 2026, a significant decline from the net income of $19.7 million in the prior year period, largely due to an $18.1 million net gain in Q2 2025 related to notes exchange and repurchases.
- 3
Adjusted EBITDA for Q2 2026 increased by 22.3% to $17.0 million, compared to $13.9 million in Q2 2025, driven by lower operational spend and higher gross margin.
- 4
Gross margin improved to 68.4% in Q2 2026 from 62.8% in Q2 2025, with adjusted gross margin reaching 71.8% compared to 65.9% in the prior year.
- 5
Operating expenses decreased by 11.6% to $45.8 million in Q2 2026, while adjusted operating expenses fell to $34.8 million, mainly due to lower personnel-related costs.
- 6
SkinHealth Systems placed 770 delivery systems during Q2 2026, a decrease from 957 systems in Q2 2025, though the active install base grew to 36,516 from 35,193.
- 7
The company revised its full-year 2026 net sales guidance to a range of $280 – $290 million and adjusted EBITDA guidance to $39 – $46 million, reflecting continued sales pressure and cost discipline.
Management Comments
Pedro Malha
Our second quarter results reflect continued sales pressure, while adjusted EBITDA came in well above our guidance range as we improved gross margin and maintained disciplined operating expense management. Our strategic priorities remain clear. We are focused on strengthening the core Hydrafacial franchise, increasing the productivity of our installed base and expanding our portfolio with complementary technologies. Supported by our trusted brand, global provider network and recurring consumables business, we believe these priorities position SkinHealth Systems to deliver more sustainable and diversified long-term growth.
Informational and educational content only. Not investment advice.